CLINICAL TRIALS PROFILE FOR GEFITINIB
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Gefitinib
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT02353741 ↗ | Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC | Terminated | Xinqiao Hospital of Chongqing | Phase 2 | 2015-04-01 | This single-arm phase II study aims to study the efficacy of a possible first line treatment that combines epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) with concurrent thoracic radiation therapy for stage IV non-small cell lung cancer (NSCLC) with active EGFR mutation, as well as assessing PFS, OS, tumor response, etc. to verify that this new combinational therapy can benefit short-term and long-term survival of the patients with advanced NSCLC. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Gefitinib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00005806 ↗ | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | 1999-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced non-small cell lung cancer. |
| NCT00005806 ↗ | Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer | Completed | Memorial Sloan Kettering Cancer Center | Phase 1 | 1999-09-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced non-small cell lung cancer. |
| NCT00006048 ↗ | ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | Unknown status | AstraZeneca | Phase 3 | 2000-05-01 | RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage IIIB or stage IV non-small cell lung cancer. |
| NCT00006049 ↗ | ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer | Unknown status | AstraZeneca | Phase 3 | 2000-05-01 | RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combination chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage III or stage IV non-small cell lung cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Gefitinib
Condition Name
Clinical Trial Locations for Gefitinib
Trials by Country
Clinical Trial Progress for Gefitinib
Clinical Trial Phase
Clinical Trial Sponsors for Gefitinib
Sponsor Name
